The agreement defines the framework for collaboration between Framatome and SNN on the production of Lutetium-177 medical radioisotopes at Romania's Cernavoda nuclear power plant. It covers the construction and operation of dedicated isotope production systems, with potential expansion to future medical isotope initiatives.
"This agreement underscores Framatome and Nuclearelectrica's commitment to strengthening the supply chain for lifesaving radioisotopes in Europe and across the globe," said Gregoire Ponchon, CEO of Framatome. "Framatome is proud to leverage its expertise in the fight against cancer and help facilitate mass access to nuclear medicine."
"2025 is significant in terms of project development and advancement at Nuclearelectrica.... We are pleased to collaborate with Framatome to supply radioisotopes for the medical community, and, at the same time, added value for our shareholders. We are here to prove the full beneficial range of the Romanian nuclear industry," said Cosmin Ghita, Chief Executive Officer of Nuclearelectrica.
Globally, over 10,000 medical facilities conduct nearly 49 million radioisotope-based procedures each year, including 10 million annually across 1,500 European centers. Lutetium-177 is a critical isotope for targeted cancer therapies, underscoring the strategic importance of the IRIS project for both healthcare and nuclear innovation.
Related Links
Framatome
Nuclear Power News - Nuclear Science, Nuclear Technology
Powering The World in the 21st Century at Energy-Daily.com
| Subscribe Free To Our Daily Newsletters |
| Subscribe Free To Our Daily Newsletters |
